Federated Hermes Inc. Has $25.62 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Federated Hermes Inc. grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 535.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 35,963 shares of the biopharmaceutical company's stock after purchasing an additional 30,304 shares during the quarter. Federated Hermes Inc.'s holdings in Regeneron Pharmaceuticals were worth $25,618,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. OFI Invest Asset Management bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth $28,000. Rakuten Securities Inc. grew its holdings in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the period. Avalon Trust Co bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $36,000. Crowley Wealth Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $36,000. Finally, Private Wealth Management Group LLC increased its holdings in shares of Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after acquiring an additional 39 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Up 1.9 %

REGN traded up $10.30 during trading on Monday, reaching $564.48. 238,981 shares of the company's stock were exchanged, compared to its average volume of 705,969. The stock has a market capitalization of $61.71 billion, a PE ratio of 14.75, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The firm has a fifty day moving average price of $659.94 and a two-hundred day moving average price of $753.23. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a one year low of $525.99 and a one year high of $1,211.20.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the company earned $11.86 EPS. Regeneron Pharmaceuticals's revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.62%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 2.30%.

Analyst Ratings Changes

Several equities analysts have commented on REGN shares. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their price objective for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Piper Sandler reduced their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a report on Monday, January 27th. JPMorgan Chase & Co. dropped their price target on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a report on Monday, March 31st. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research report on Wednesday, January 8th. Finally, Bernstein Bank decreased their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $966.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.